Comparing two medicines for fatty liver disease
Treatments studied
Part of Digestive system clinical trials.
This study compares two common medications—empagliflozin (a diabetes drug) and statins (cholesterol-lowering drugs)—to see which works better for people with fatty liver disease who also have diabetes and high cholesterol. It aims to find a treatment that helps improve liver health while also managing these related conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You are considered obese
- You have diabetes
- You have high cholesterol or high fats in your blood
- You have been diagnosed with non-alcoholic fatty liver disease or non-alcoholic steatohepatitis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two diabetes pills (pioglitazone and empagliflozin) to see if they can reduce liver fat in people with type 2 diabetes and fatty liver disease. It may help if your diabetes is not well controlled and you have a fatty liver confirmed by a special ultrasound scan.
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
This Phase 2 study tests whether low-dose pioglitazone can improve NASH, a type of fatty liver disease, in adults who also have type 2 diabetes. You may be able to join if your diabetes medicines and lab tests meet specific safety and stability requirements.
This study tests a new diabetes medicine called Enavogliflozin against an older drug, Pioglitazone, to see which works better for lowering blood sugar and improving heart health. If you have type 2 diabetes, take metformin plus another pill, and your A1C is between 7 and 10.5, this study may be an option for you.
This study looks at how the liver uses energy (mitochondria) in people with type 2 diabetes and fatty liver disease. By understanding this, researchers may find better ways to treat liver problems.
This trial tests whether pioglitazone or empagliflozin is better at managing diabetes caused by chronic or recurrent pancreatitis. You will take one of these pills daily for 6 months and track your blood sugar and ketones at home. The goal is to find a safer, more effective treatment for this type of diabetes.
Hear when a new Non-alcoholic Fatty Liver Disease NAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.